

## ASX Announcement 24 October 2022

## **OPTISCAN RECEIVES R&D TAX INCENTIVE REBATE**

Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'Optiscan') is pleased to advise that the Company has received its R&D Tax Incentive rebate for the 2021/2022 financial year amounting to \$941,790. The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

The R&D receivable amount to 30 June 2022 was accounted for in the Statement of Financial Position as at 30 June 2022.

- ends -

This announcement has been authorised for release by the Board of Optiscan.

## For investor queries, please contact:

Camile Farah
CEO & Managing Director – Optiscan Imaging Limited
E: cfarah@optiscan.com

## **About Optiscan**

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, in-vivo imaging at the sub-cellular level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pensized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.